Global real-world evidence firm expands access team
International real-world evidence (RWE) leader Certara® (NJ, USA) has announced the expansion of its Evidence & Access group with the addition of the staff of Compass Strategic Consulting (CT, USA).
Global leader in model-based drug development, market access and real-world evidence (RWE), Certara® (NJ, USA), has announced the addition of the Compass Strategic Consulting (CT, USA) team to their Evidence & Access group, in a move that aims to increase patient access to potentially curative therapies and novel drugs.
The Certara Evidence & Access group formed following Certara’s acquisition of Analytica Laser (London, UK) and BaseCase (Berlin, Germany), experts in health economics and RWE, and life sciences value communication respectively.
The Compass Strategic Consulting team have 2 decades of experience in the marketing of drugs and medical devices in a range of care settings, with particular expertise in drugs indicated for the treatment of rare disease.
Compass Strategic Consulting has previously partnered with Analytica Laser.
Roman Casciano, Certara Evidence & Access Senior Vice President, commented: “Determining cost versus value for novel drug therapies is an economic and ethical issue impacting healthcare around the world, and it is at the heart of our expanded offering.”
The expansion aims to leverage Compass' experience in developing drug access strategies, with Certara’s Evidence & Access strengths in product value propositions, to support health technology assessment.
Paul Gallagher, Vice President of Certara US Access Strategy, stated: “Partnering with Certara, which has a vast global reach and expertise in regulatory science and drug development, provides a win-win situation for our clients who are referred to us because of our deep understanding of the complex and segmented US healthcare delivery and payment systems.”
Gallagher continued: “One of our unique advantages, which allows us to identify and understand disruptive trends and initiatives in the marketplace…is the Compass Expert Panel... Having access to this expertise is critically important as the industry grapples with payment options for complex and potentially curative new treatments, such as gene and cell therapies.”